Boston Scientific Corporation $BSX Shares Bought by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. increased its position in Boston Scientific Corporation (NYSE:BSX) by 136.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,423 shares of the medical equipment provider’s stock after buying an additional 1,977 shares during the period. Geneos Wealth Management Inc.’s holdings in Boston Scientific were worth $345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. HM Payson & Co. increased its stake in Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares during the last quarter. Park Square Financial Group LLC boosted its holdings in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after purchasing an additional 103 shares during the last quarter. HHM Wealth Advisors LLC increased its stake in Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 103 shares during the last quarter. Rise Advisors LLC lifted its holdings in shares of Boston Scientific by 13.9% during the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 103 shares in the last quarter. Finally, Forum Financial Management LP boosted its holdings in Boston Scientific by 0.8% in the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider’s stock worth $1,357,000 after acquiring an additional 112 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Truist Financial lifted their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Finally, Raymond James Financial boosted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $118.04.

Boston Scientific Stock Down 2.9%

Shares of BSX stock opened at $99.75 on Tuesday. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $147.80 billion, a PE ratio of 59.38, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65. The stock has a 50 day moving average of $104.78 and a 200-day moving average of $102.24.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the business posted $0.62 EPS. The business’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $18,397,457. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.